delanzomib and ixazomib share 3 molecular targets based on binding affinity data from BindingDB (Kd/IC50 ≤ 10 µM) and ChEMBL. A Jaccard index of 0.333 means 33% of the combined target set is bound by both compounds. The IDF-weighted score of 0.306 accounts for non-specific binding to metabolic enzymes.
Note: High target overlap does not imply identical mechanism or therapeutic equivalence. Binding affinity, tissue distribution, bioavailability, and downstream signaling differ significantly between compounds even when they bind the same protein.
Frequently Asked Questions
What do delanzomib and ixazomib have in common?
delanzomib and ixazomib share 3 molecular targets with a Jaccard similarity of 33%. Both bind overlapping sets of proteins based on BindingDB and ChEMBL binding affinity data.
Can delanzomib and ixazomib be combined?
delanzomib and ixazomib share 3 molecular targets, suggesting potential pathway overlap. Combination use should be evaluated with a qualified healthcare professional. BiohacksAI does not provide medical advice.
Which has more research: delanzomib or ixazomib?
In the BiohacksAI corpus: delanzomib has 0 PubMed-indexed studies, ixazomib has 0 studies.